ContributorsPublishersAdvertisers

The characteristics of patents impacting availability of biosimilars

Nature.com
 2022-01-18

The large number of biologic drug patents in the United States has contributed to delays in biosimilar availability. Biologic drugs such as monoclonal antibodies and gene therapies have become mainstays in the treatment of many diseases, but also focal points in the debate over pharmaceutical pricing. Biologics accounted for 48% of...

www.nature.com

Comments / 0

Comments / 0